Compare Agilent Technologies Inc (A) vs JPMorgan Equity Premium Income ETF (JEPI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Agilent Technologies Inc vs JPMorgan Equity Premium Income ETF — how do they compare? Agilent Technologies Inc trades at $149.35 (market cap $42.00B), while JPMorgan Equity Premium Income ETF trades at $57.86. The key difference: Agilent Technologies Inc pays a 0.69% dividend while JPMorgan Equity Premium Income ETF pays none, and Agilent Technologies Inc is trading nearer its 52-week high, JPMorgan Equity Premium Income ETF nearer its low. Which is the better fit depends on your goals.
| A | JEPI | |
|---|---|---|
Market Cap | $42.00B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $157.20 | $59.88 |
52-Week Low | $110.24 | $55.29 |
Enterprise Value | $43.55B | — |
Dividend Yield | 0.69% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Agilent Technologies (A) trades at $145.97, up 3.28% in the last session, with a bullish technical outlook from moving averages but overbought RSI levels. The company reported strong Q1 2026 earnings, beating estimates with EPS of $1.49, and maintains solid profitability with a net income margin of 19.55%. Recent developments include FDA and EU approvals for diagnostic assays and the acquisition of Biocare Medical, enhancing its healthcare portfolio.
The stock offers upside to the consensus price target of $154.90, supported by analyst optimism (77.5% buy ratings), but high valuation ratios like a P/E of 146.56 pose risks. Investors should monitor execution of growth initiatives and competitive pressures in the life sciences sector, with earnings on August 26, 2026, as a key catalyst.
JEPI trades at $57.58, showing minimal daily change. Technical indicators are bullish overall, with strong moving average support but a neutral oscillator reading. Recent news highlights its role in income strategies, though some articles note underperformance versus peers. The ETF's covered-call strategy provides monthly income but may limit capital appreciation.
The outlook is mixed: JEPI offers reliable income with a covered-call approach, appealing for risk-averse investors. However, competition from higher-yielding ETFs and potential tax inefficiencies pose risks. Investors should weigh income stability against growth opportunity costs in a rising market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Agilent Technologies Inc
Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life sciences and diagnostics firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and applied tools (45% of fiscal 2021 sales), cross lab (35% of sales consisting of consumables and services related to its life science and applied tools), and diagnostics and genomics (20%). Over half of its sales are generated from the biopharmaceutical, chemical, and energy end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the U.S. (34%) and China (20%) representing the largest country concentrations.
Read more on A →About JPMorgan Equity Premium Income ETF
JEPI is an actively managed ETF that seeks to deliver monthly income and stock market exposure with lower volatility. It combines an equity portfolio with an options strategy to generate steady premiums.
Read more on JEPI →
